MCID: ALP009
MIFTS: 64

Alopecia Areata

Categories: Rare diseases, Skin diseases, Immune diseases

Aliases & Classifications for Alopecia Areata

MalaCards integrated aliases for Alopecia Areata:

Name: Alopecia Areata 12 72 49 28 51 41 14 69
Cazenave's Vitiligo 49 69
Jonston's Alopecia 49 69
Marginal Alopecia 49 69
Celsus' Vitiligo 49 69
Diffuse Alopecia 49 69
Alopecia Celsi 49 69
Circumscribed Alopecia 12
Alopecia Circumscripta 49
Alopecia Cicatrisata 49
Patchy Alopecia 49
Pseudopelade 69
Alopecia 69
Aa 49

Classifications:



External Ids:

Disease Ontology 12 DOID:986
ICD10 32 L63 L63.9 L66.0
ICD9CM 34 704.01
MeSH 41 D000506

Summaries for Alopecia Areata

NIH Rare Diseases : 49 Alopecia areata (AA) is an autoimmune disease in which the immune system mistakenly attacks the hair follicles. In most cases, hair falls out in small, round patches on the scalp. Although uncommon, hair loss can be more extensive in some people and affect other parts of the body. This condition can progress to complete loss of scalp hair (alopecia totalis) or total loss of all body hair (alopecia universalis). Although the exact cause of AA is unknown, roughly 20% of affected people have a family member with alopecia, suggesting that genetic factors may contribute to the development of the condition. There is no cure or approved therapy for AA; however, some people find that medications approved for other purposes can help regrow hair. Last updated: 11/23/2014

MalaCards based summary : Alopecia Areata, also known as cazenave's vitiligo, is related to aplastic anemia and alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity, and has symptoms including pruritus and exanthema. An important gene associated with Alopecia Areata is AA1 (Alopecia Areata 1), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Minoxidil and Finasteride have been mentioned in the context of this disorder. Affiliated tissues include breast, brain and skin, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A hypersensitivity reaction type II disease resulting in the loss of hair on the scalp and elsewhere on the body initially causing bald spots.

Wikipedia : 72 Alopecia areata, also known as spot baldness, is a condition in which hair is lost from some or all... more...

Related Diseases for Alopecia Areata

Diseases in the Alopecia Areata family:

Alopecia Areata 1 Alopecia Areata 2

Diseases related to Alopecia Areata via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 292)
# Related Disease Score Top Affiliating Genes
1 aplastic anemia 31.4 FASLG HLA-A IFNG IL2 TNF
2 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.4 AIRE CTLA4 IFNG PTPN22
3 vitiligo-associated multiple autoimmune disease susceptibility 1 31.3 AIRE CTLA4 PTPN22
4 chronic mucocutaneous candidiasis 30.7 AIRE IFNG IL2RA
5 thyroiditis 30.5 CTLA4 FASLG IFNG IL2
6 temporal arteritis 30.4 IFNG IL1RN PTPN22
7 helicobacter pylori infection 30.3 IFNG IL1RN TNF
8 contact dermatitis 30.3 ICAM1 IFNG IL1A TNF
9 arthritis 30.3 IFNG IL1A IL1RN PTPN22 TNF
10 dermatitis, atopic 30.3 ICAM1 IFNG IL2 IL2RA TNF
11 diabetes mellitus 30.2 AIRE CTLA4 IL2RA PTPN22 TNF
12 herpes zoster 30.2 HLA-A IFNG IL2
13 thymoma 30.1 AIRE CTLA4 IL2
14 allergic contact dermatitis 30.1 ICAM1 IFNG TNF
15 leprosy 3 30.1 IFNG IL2 TNF
16 lichen planus 30.1 GZMB ICAM1 IFNG TNF
17 myasthenia gravis 30.1 AIRE CTLA4 IFNG IL2 TNF
18 intermediate uveitis 30.0 IFNG IL2 IL2RA TNF
19 keratoconjunctivitis 29.8 ICAM1 IFNG IL2 TNF
20 psoriasis 29.8 CXCL10 ICAM1 IFNG IL1A IL2 IL2RA
21 lymphopenia 29.7 FASLG IFNG IL2 IL2RA
22 cutaneous lupus erythematosus 29.7 GZMB ICAM1 TNF
23 autoimmune disease 29.7 AIRE CTLA4 IFNG IL1RN IL2 IL2RA
24 mycosis fungoides 29.6 CTLA4 CXCL10 GZMB IL2 IL2RA
25 graves' disease 29.5 CTLA4 FASLG ICAM1 IFNG IL2RA PTPN22
26 uveitis 29.3 CTLA4 CXCL10 ICAM1 IFNG IL1A IL2RA
27 rheumatoid arthritis 29.2 CTLA4 ICAM1 IFNG IL1A IL1RN IL2
28 inflammatory bowel disease 28.8 CTLA4 CXCL10 ICAM1 IFNG IL1A IL1RN
29 celiac disease 1 28.8 CTLA4 GZMB HLA-A IFNG IL2 PTPN22
30 hashimoto thyroiditis 28.6 AIRE CTLA4 FASLG ICAM1 IFNG IL2
31 systemic lupus erythematosus 28.3 CTLA4 CXCL10 FASLG ICAM1 IFNG IL2
32 diffuse alopecia areata 12.5
33 alopecia areata 1 12.4
34 amyloidosis aa 12.4
35 helsmoortel-van der aa syndrome 12.3
36 alopecia universalis congenita 12.2
37 alopecia areata 2 12.2
38 adnp syndrome 11.7
39 alopecia totalis 11.7
40 williams-beuren region duplication syndrome 11.5
41 nail disorder, nonsyndromic congenital, 1 11.4
42 alopecia 11.2
43 cutaneous telangiectasia and cancer syndrome, familial 11.1
44 renal nutcracker syndrome 11.1
45 sveinsson chorioretinal atrophy 11.1
46 aarskog-scott syndrome 11.1
47 mental retardation, x-linked, syndromic, claes-jensen type 11.1
48 t-cell receptor-alpha/beta deficiency 11.1
49 bier spots 11.1
50 superior mesenteric artery syndrome 11.0

Graphical network of the top 20 diseases related to Alopecia Areata:



Diseases related to Alopecia Areata

Symptoms & Phenotypes for Alopecia Areata

UMLS symptoms related to Alopecia Areata:


pruritus, exanthema

GenomeRNAi Phenotypes related to Alopecia Areata according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 TNF GZMB ICAM1 IL1A IL2 IL2RA
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 IL2RA TNF FASLG GZMB ICAM1 IL1A

MGI Mouse Phenotypes related to Alopecia Areata:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.2 MC2R PTPN22 TNF IL2 IL1RN ICAM1
2 hematopoietic system MP:0005397 10.18 MC2R PTPN22 TNF IL2RA IL2 AIRE
3 homeostasis/metabolism MP:0005376 10.13 IL2RA MC2R PTPN22 TNF IL2 IL1RN
4 endocrine/exocrine gland MP:0005379 10.1 IL2RA MC2R PTPN22 TNF IL2 FASLG
5 digestive/alimentary MP:0005381 10.09 IL2RA PTPN22 TNF IL2 AIRE ICAM1
6 immune system MP:0005387 10.07 MC2R PTPN22 TNF IL2RA IL2 AIRE
7 liver/biliary system MP:0005370 9.7 PTPN22 TNF IL2 FASLG AIRE CTLA4
8 neoplasm MP:0002006 9.5 TNF IL2 FASLG AIRE ICAM1 IFNG
9 respiratory system MP:0005388 9.23 IL2RA PTPN22 TNF IL2 FASLG AIRE

Drugs & Therapeutics for Alopecia Areata

Drugs for Alopecia Areata (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 372)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Minoxidil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 38304-91-5 4201
2
Finasteride Approved Phase 4,Phase 3,Phase 1,Phase 2 98319-26-7 57363
3
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
4
Acitretin Approved Phase 4 55079-83-9 5284513 6437841
5
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
6
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
7
Clobetasol Approved, Investigational Phase 4,Phase 3 25122-41-2, 25122-46-7 5311051 32798
8
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 3 23214-92-8 31703
9
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
10
Spironolactone Approved Phase 4,Phase 2 1952-01-7, 52-01-7 5833
11
Drospirenone Approved Phase 4 67392-87-4 68873
12
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
13
Hydroxychloroquine Approved Phase 4 118-42-3 3652
14
Capsaicin Approved Phase 4 404-86-4 1548943
15
Imiquimod Approved, Investigational Phase 4,Phase 3 99011-02-6 57469
16
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
17
Hydroxocobalamin Approved Phase 4 13422-51-0 5460373 44475014 11953898
18
Bimatoprost Approved, Investigational Phase 4,Phase 2,Phase 1 155206-00-1 5311027
19
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
20
Apremilast Approved, Investigational Phase 4,Phase 2 608141-41-9 11561674
21
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
23
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854
24
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 4 13422-55-4
25
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
26 Orange Approved, Nutraceutical Phase 4
27
Doxil Approved June 1999 Phase 4,Phase 2,Phase 3 31703
28 triamcinolone acetonide Phase 4,Phase 2
29 Prednisolone acetate Phase 4
30 Analgesics Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
31 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
32 5-alpha Reductase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
33 Respiratory System Agents Phase 4,Phase 1,Phase 2
34 Methylprednisolone acetate Phase 4
35 Methylprednisolone Hemisuccinate Phase 4
36 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
37 Micronutrients Phase 4,Phase 1,Phase 2
38 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
39 Gastrointestinal Agents Phase 4,Phase 2,Phase 1
40 Neuroprotective Agents Phase 4,Phase 2
41 Trace Elements Phase 4,Phase 1,Phase 2
42 Triamcinolone diacetate Phase 4,Phase 2
43 Triamcinolone hexacetonide Phase 4,Phase 2
44 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 1,Phase 2
45 Vasodilator Agents Phase 4,Phase 3,Phase 1,Phase 2
46 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
47 Dermatologic Agents Phase 4,Phase 3,Phase 1,Phase 2
48 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
49 Hormones Phase 4,Phase 3,Phase 1,Phase 2
50 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 339)

# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia Unknown status NCT01111981 Phase 4 Clobetasol Propionate 0.05% Emollient Foam
2 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
3 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
4 Aldara for the Treatment of Extensive Alopecia Areata Completed NCT00177021 Phase 4 Aldara Cream 5%
5 Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5% Completed NCT00176943 Phase 4 Aldara Cream 5%
6 Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata Completed NCT02350023 Phase 4 Topical latanoprost 0.005%;Topical betamethasone 0.05%
7 Plaquenil for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4 Hydroxychloroquine
8 Response of Topical Capsaicin in Alopecia Areata Completed NCT00176969 Phase 4 Capsaicin
9 Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata Completed NCT01167946 Phase 4 methylprednisolone sodium succinate;methylprednisolone sodium succinate;methylprednisolone sodium succinate
10 Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children Completed NCT01023841 Phase 4 bimatoprost ophthalmic solution 0.03%;Vehicle Sterile Solution
11 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
12 Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses Completed NCT00774787 Phase 4 imiquimod 5% cream
13 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4 Drospirenone Ethinyl estradiol;Drospirenone Ethinyl estradiol Myo-inositol;placebo
14 Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound Parameters Completed NCT01514942 Phase 4 Folic acid, vit B12;Folic acid, vit B12
15 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
16 Intralesional Steroids in the Treatment of Alopecia Areata Recruiting NCT01898806 Phase 4 Intralesional Triamcinolone 2.5 mg/ml;Intralesional Triamcinolone 5 mg/ml;Intralesional Triamcinolone 10 mg/ml;Intralesional Saline
17 Adipose Derived Stem Cells Versus Platelet Rich Plasma on Follicular Unit Extraction Recruiting NCT03388840 Phase 4
18 Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia Active, not recruiting NCT02999737 Phase 4
19 Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia Not yet recruiting NCT03422640 Phase 4 Apremilast
20 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
21 Topical Garlic Concentrate for Alopecia Areata in Children Unknown status NCT02691117 Phase 3 garlic concentrate
22 Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients Unknown status NCT01655108 Phase 3 Minoxidil;Saline
23 Reflexology's Effect on Polycystic Ovary Syndrome: A Pilot Study Unknown status NCT00746148 Phase 3
24 Reflexology's Effect on Polycystic Ovary Syndrome (PCOS) Unknown status NCT00744510 Phase 3
25 Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous Unknown status NCT01222000 Phase 3 apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side;apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
26 Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata Completed NCT00063076 Phase 2, Phase 3 Targretin Gel 1%
27 A Trial of Clobetasol Propionate Versus Hydrocortisone in Children With Alopecia Areata Completed NCT01453686 Phase 3 Hydrocortisone 1%;Clobetasol Propionate 0.05%
28 The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis Completed NCT00997815 Phase 2, Phase 3 Botulinum toxin A;Normal saline injection
29 Clinical Trial in Females for Female Pattern Hair Loss Completed NCT01226459 Phase 3 5% Minoxidil Topical Foam;Vehicle Topical Foam
30 Clinical Trial in Females With Female Pattern Hair Loss Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
31 Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia Completed NCT00958750 Phase 3 minoxidil
32 A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Completed NCT00151515 Phase 3 minoxidil
33 A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
34 A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
35 Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
36 Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss Completed NCT01391156 Phase 3 3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion
37 Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
38 Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM) Completed NCT01590238 Phase 3
39 Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111) Completed NCT00396175 Phase 3 MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
40 Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up Completed NCT02549352 Phase 3 LEO43204 gel;Vehicle gel
41 Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up Completed NCT02547363 Phase 3 LEO 43204 gel;Vehicle gel
42 A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp Completed NCT02611804 Phase 3 Diclofenac sodium;Diclofenac sodium;Placebo
43 Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis Completed NCT01686152 Phase 3 Imiquimod Cream, 3.75%;Zyclara®
44 Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest Completed NCT02361216 Phase 3 Ingenol Mebutate
45 Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs) Completed NCT00603798 Phase 3 Imiquimod cream;Placebo cream;Imiquimod cream
46 Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs) Completed NCT00605176 Phase 3 imiquimod cream;imiquimod cream;Placebo
47 Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117767 Phase 3 Terbinafine hydrochloride (HCl);Griseofulvin
48 Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117754 Phase 3 Terbinafine hydrochloride
49 A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Subjects With Actinic Keratoses Completed NCT02120898 Phase 3 Imiquimod
50 Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis Completed NCT02616601 Phase 3 Carac Cream;Generic Fluorouracil Cream;Placebo

Search NIH Clinical Center for Alopecia Areata

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: alopecia areata

Genetic Tests for Alopecia Areata

Genetic tests related to Alopecia Areata:

# Genetic test Affiliating Genes
1 Alopecia Areata 28

Anatomical Context for Alopecia Areata

MalaCards organs/tissues related to Alopecia Areata:

38
Breast, Brain, Skin, Ovary, Testes, T Cells, Lung

Publications for Alopecia Areata

Articles related to Alopecia Areata:

(show top 50) (show all 795)
# Title Authors Year
1
Applying the Common Sense Model to predicting quality of life in alopecia areata: The role of illness perceptions and coping strategies. ( 29355049 )
2018
2
Alopecia Areata: The Clinical Situation. ( 29273111 )
2018
3
Big Data Reveal Insights into Alopecia Areata Comorbidities. ( 29273109 )
2018
4
Reply to: "Tofacitinib for the treatment of severe alopecia areata and variants". ( 29332724 )
2018
5
Topical Immunotherapy of Alopecia Areata: A Large Retrospective Study. ( 29442292 )
2018
6
Alopecia areata after dupilumab for atopic dermatitis. ( 29387767 )
2018
7
Annular Alopecia Areata: A Morphologically Rare Variant. ( 29440858 )
2018
8
An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch Type Alopecia Areata, Totalis and Universalis. ( 29452121 )
2018
9
Hemorrhagic Ischemic Retinal Vasculitis and Alopecia Areata as a Manifestation of HLA-B27. ( 29304269 )
2018
10
Genetic analysis of interleukin 18 gene polymorphisms in alopecia areata. ( 29349811 )
2018
11
Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children, and their families. ( 29425723 )
2018
12
Development of Frontal Fibrosing Alopecia with a History of Alopecia Areata. ( 29440856 )
2018
13
Nail changes in alopecia areata: an update and review. ( 29318582 )
2018
14
Cytokine Targeted Therapeutics forA Alopecia Areata: Lessons fromA Atopic Dermatitis and OtherA Inflammatory Skin Diseases. ( 29273110 )
2018
15
Three Cases of Radiation-induced Temporary Alopecia with Hair Microscopic Examination: "Coudability Hair" Might Not be Specific for Alopecia Areata. ( 29440860 )
2018
16
Differential proteomics of lesional vs. non-lesional biopsies revealed non-immune mechanisms of alopecia areata. ( 29323127 )
2018
17
Is there an association of ABO blood groups and Rhesus factor with alopecia areata? ( 29336112 )
2018
18
Childhood alopecia areata-Data from the National Alopecia Areata Registry. ( 29334143 )
2018
19
Alopecia areata as a paraneoplastic syndrome of gastric cancer. ( 27990839 )
2017
20
Lack of efficacy of apremilast in 9 patients with severe alopecia areata. ( 28917463 )
2017
21
Long-term result of hair transplantation for therapy resistant alopecia areata of eyebrows. ( 28731020 )
2017
22
Alopecia Areata: a Comprehensive Review of Pathogenesis and Management. ( 28717940 )
2017
23
Alopecia areata complicated with Good's syndrome. ( 28925501 )
2017
24
UVA-1 in the treatment of alopecia areata. ( 28834031 )
2017
25
Tofacitinib for the treatment of alopecia areata and variants in adolescents. ( 27816292 )
2017
26
Efficacy of combining pulse corticotherapy and methotrexate in alopecia areata: Real-life evaluation. ( 28940756 )
2017
27
Nilotinib-induced Keratosis Pilaris Associated with Alopecia Areata and Eyebrow Thinning. ( 28839396 )
2017
28
Role of T helper 17 cells and T regulatory cells in alopecia areata: comparison of lesion and serum cytokine between controls and patients. ( 29283462 )
2017
29
Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata. ( 28044367 )
2017
30
Common phenotype and different non-HLA genes in Graves' disease and alopecia areata. ( 27810496 )
2017
31
Unsuccessful Treatment of Alopecia Areata with Simvastatin/Ezetimibe: Experience in 12 Patients. ( 28879192 )
2017
32
A Case Report of Verruca Vulgaris on basis of Alopecia Areata Successfully Treated with Diphenylcyclopropenone. ( 28761264 )
2017
33
Alopecia Areata on Vertex as a Potential Pitfall for Misdiagnosis of Central Centrifugal Cicatricial Alopecia in African-American Women. ( 28839392 )
2017
34
Trichotillomania: a case report with clinical and dermatoscopic differential diagnosis with alopecia areata. ( 28225970 )
2017
35
Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. ( 27816293 )
2017
36
Trichoscopic clues for diagnosis of alopecia areata and trichotillomania in Asians. ( 28074524 )
2017
37
Evaluation of the Relationship between Alopecia Areata and Viral Antigen Exposure. ( 28801732 )
2017
38
Lupus erythematosus tumidus of the scalp masquerading as alopecia areata. ( 28319635 )
2017
39
"i hair": A prognostic marker in alopecia areata & trichotillomania. ( 29263543 )
2017
40
A Case of Alopecia Areata in a Patient with Turner Syndrome. ( 28785342 )
2017
41
Increased blood levels of NKG2D(+)CD4(+) TA cells in patients with alopecia areata. ( 27986136 )
2017
42
Home-based contact immunotherapy with diphenylcyclopropenone for alopecia areata is as effective and safe as clinic-based treatment in patients with stable disease: A retrospective study of 40 patients. ( 28947296 )
2017
43
Bullying and Quality of Life in Pediatric Alopecia Areata. ( 28879186 )
2017
44
Vitamin D Level in Alopecia Areata. ( 28794553 )
2017
45
Increased expression of PD-L1 and PD-L2 in dermal fibroblasts from alopecia areata mice. ( 28777458 )
2017
46
Ausschreibung Forschungspreis Alopecia areata. ( 28872235 )
2017
47
Minoxidil-Induced Hypertrichosis in a Child with Alopecia Areata. ( 28405563 )
2017
48
Establishing and Prioritising Research Questions for the Prevention, Diagnosis and Treatment of Hair Loss (excluding Alopecia Areata): The Hair Loss Priority Setting Partnership. ( 28714061 )
2017
49
Large Scale Epitope Identification Screen and Its Potential Application to the Study of Alopecia Areata. ( 28864075 )
2017
50
A retrospective comparative study of the efficacy and safety of two regimens of diphenylcyclopropenone in the treatment of recalcitrant alopecia areata. ( 29299216 )
2017

Variations for Alopecia Areata

ClinVar genetic disease variations for Alopecia Areata:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 TRPS1 NM_014112.4(TRPS1): c.2794G> A (p.Ala932Thr) single nucleotide variant Pathogenic/Likely pathogenic rs1057518972 GRCh37 Chromosome 8, 116430587: 116430587

Expression for Alopecia Areata

Search GEO for disease gene expression data for Alopecia Areata.

Pathways for Alopecia Areata

Pathways related to Alopecia Areata according to GeneCards Suite gene sharing:

(show all 45)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 CTLA4 CXCL10 FASLG HLA-A ICAM1 IFNG
2
Show member pathways
13.37 CXCL10 FASLG HLA-A ICAM1 IFNG IL1A
3
Show member pathways
13.29 CXCL10 FASLG IL1A IL2 IL2RA PTPN22
4
Show member pathways
12.75 CXCL10 FASLG HLA-A ICAM1 IFNG IL1A
5
Show member pathways
12.7 CTLA4 FASLG GZMB HLA-A ICAM1 IFNG
6
Show member pathways
12.6 IFNG IL1A IL2 IL2RA TNF
7
Show member pathways
12.53 CXCL10 FASLG IFNG IL2 TNF
8
Show member pathways
12.45 FASLG GZMB HLA-A ICAM1 IFNG IL2
9
Show member pathways
12.43 CTLA4 IFNG IL1A IL2 TNF
10 12.42 HLA-A ICAM1 IL2 IL2RA TNF
11
Show member pathways
12.32 ICAM1 IFNG IL2 TNF
12
Show member pathways
12.25 FASLG GZMB IL1A TNF
13
Show member pathways
12.22 FASLG IFNG IL1A TNF
14
Show member pathways
12.19 CXCL10 FASLG IFNG TNF
15
Show member pathways
12.18 HLA-A IFNG IL1A IL2 TNF
16 12.09 ICAM1 IFNG IL1A TNF
17 12.03 CXCL10 ICAM1 IFNG IL1A IL2 TNF
18 12 IFNG IL2 IL2RA TNF
19 11.99 FASLG ICAM1 IL1A TNF
20
Show member pathways
11.96 FASLG GZMB HLA-A IFNG IL2 IL2RA
21 11.88 CTLA4 ICAM1 IFNG IL1A TNF
22 11.86 IL1A IL2RA TNF
23 11.84 CTLA4 CXCL10 FASLG GZMB IFNG IL1RN
24 11.81 GZMB IFNG IL2 IL2RA TNF
25 11.78 ICAM1 IFNG IL2
26 11.73 IFNG IL2 TNF
27 11.71 CTLA4 ICAM1 IL2RA TNF
28
Show member pathways
11.69 ICAM1 IFNG IL1A IL2 TNF
29
Show member pathways
11.68 FASLG IL2 IL2RA
30
Show member pathways
11.68 CTLA4 FASLG IFNG IL2 IL2RA TNF
31 11.59 FASLG IFNG IL2 TNF
32 11.54 ICAM1 IFNG TNF
33 11.54 CXCL10 ICAM1 IL1A IL1RN TNF
34 11.52 IFNG IL2 TNF
35 11.52 FASLG IFNG IL1A TNF
36 11.5 IFNG IL2 IL2RA
37 11.47 FASLG ICAM1 IFNG
38 11.39 CXCL10 ICAM1 IFNG
39 11.39 FASLG ICAM1 IFNG TNF
40 11.33 IFNG IL2 IL2RA
41 11.31 IFNG IL1A IL2 TNF
42
Show member pathways
11.29 FASLG GZMB HLA-A IFNG IL2 IL2RA
43 11.23 IFNG IL2 IL2RA
44 11.23 CXCL10 FASLG IL1A IL2 TNF
45
Show member pathways
11.19 FASLG GZMB IFNG IL2 IL2RA TNF

GO Terms for Alopecia Areata

Cellular components related to Alopecia Areata according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 CXCL10 FASLG ICAM1 IFNG IL1A IL1RN
2 external side of plasma membrane GO:0009897 9.1 CTLA4 CXCL10 FASLG ICAM1 IL2RA TNF

Biological processes related to Alopecia Areata according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.97 CTLA4 HLA-A IL2 IL2RA PTPN22
2 inflammatory response GO:0006954 9.92 CXCL10 IL1A IL1RN IL2RA TNF
3 response to lipopolysaccharide GO:0032496 9.85 CXCL10 FASLG ICAM1 PTPN22
4 interferon-gamma-mediated signaling pathway GO:0060333 9.73 HLA-A ICAM1 IFNG
5 humoral immune response GO:0006959 9.71 AIRE IFNG TNF
6 regulation of receptor activity GO:0010469 9.7 CXCL10 FASLG IFNG IL1A IL1RN IL2
7 positive regulation of nitric oxide biosynthetic process GO:0045429 9.61 ICAM1 IFNG TNF
8 negative regulation of immune response GO:0050777 9.58 CTLA4 IL2RA
9 extrinsic apoptotic signaling pathway GO:0097191 9.58 FASLG IFNG TNF
10 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.51 ICAM1 TNF
11 negative regulation of lymphocyte proliferation GO:0050672 9.49 IL2 IL2RA
12 necroptotic signaling pathway GO:0097527 9.48 FASLG TNF
13 fever generation GO:0001660 9.46 IL1A IL1RN
14 regulation of T cell homeostatic proliferation GO:0046013 9.37 IL2 IL2RA
15 immune response GO:0006955 9.36 AIRE CTLA4 CXCL10 FASLG HLA-A IFNG
16 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.32 IFNG TNF
17 positive regulation of vitamin D biosynthetic process GO:0060557 9.26 IFNG TNF
18 regulation of regulatory T cell differentiation GO:0045589 9.26 CTLA4 IFNG IL2 IL2RA

Molecular functions related to Alopecia Areata according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.89 AIRE CTLA4 CXCL10 FASLG GZMB HLA-A
2 cytokine activity GO:0005125 9.17 CXCL10 FASLG IFNG IL1A IL1RN IL2

Sources for Alopecia Areata

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....